<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ge C</submitter><funding>China Postdoctoral Science Foundation</funding><funding>National Natural Science Foundation of China</funding><funding>Nanjing Science and Technology Development Foundation</funding><funding>Jiangsu postdoctoral grant program</funding><pagination>14</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9887786</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>23(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>As a prodrug of 5-fluorouracil (5-FU), orally administrated capecitabine (CAP) undergoes preliminary conversion into active metabolites in the liver and then releases 5-FU in the gut to exert the anti-tumor activity. Since metabolic changes of CAP play a key role in its activation, a single kind of intestinal or hepatic cell can never be used in vitro to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) nature. Hence, we aimed to establish a novel in vitro system to effectively assess the PK and PD of these kinds of prodrugs.&lt;h4>Methods&lt;/h4>Co-culture cellular models were established by simultaneously using colorectal cancer (CRC) and hepatocarcinoma cell lines in one system. Cell Counting Kit-8 (CCK-8) and flow cytometric analysis were used to evaluate cell v</pubmed_abstract><journal>Cancer cell international</journal><pubmed_title>In vitro co-culture systems of hepatic and intestinal cells for cellular pharmacokinetic and pharmacodynamic studies of capecitabine against colorectal cancer.</pubmed_title><pmcid>PMC9887786</pmcid><funding_grant_id>2018Z092</funding_grant_id><funding_grant_id>81803624</funding_grant_id><funding_grant_id>202205029</funding_grant_id><funding_grant_id>81803622</funding_grant_id><funding_grant_id>2018M640498</funding_grant_id><pubmed_authors>Ge C</pubmed_authors><pubmed_authors>Zou J</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Zhu Y</pubmed_authors><pubmed_authors>Xu C</pubmed_authors><pubmed_authors>Feng D</pubmed_authors><pubmed_authors>Yuan M</pubmed_authors><pubmed_authors>Zhang S</pubmed_authors><pubmed_authors>Jie Q</pubmed_authors><pubmed_authors>Aa J</pubmed_authors><pubmed_authors>Tan Z</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Huang X</pubmed_authors></additional><is_claimable>false</is_claimable><name>In vitro co-culture systems of hepatic and intestinal cells for cellular pharmacokinetic and pharmacodynamic studies of capecitabine against colorectal cancer.</name><description>&lt;h4>Background&lt;/h4>As a prodrug of 5-fluorouracil (5-FU), orally administrated capecitabine (CAP) undergoes preliminary conversion into active metabolites in the liver and then releases 5-FU in the gut to exert the anti-tumor activity. Since metabolic changes of CAP play a key role in its activation, a single kind of intestinal or hepatic cell can never be used in vitro to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) nature. Hence, we aimed to establish a novel in vitro system to effectively assess the PK and PD of these kinds of prodrugs.&lt;h4>Methods&lt;/h4>Co-culture cellular models were established by simultaneously using colorectal cancer (CRC) and hepatocarcinoma cell lines in one system. Cell Counting Kit-8 (CCK-8) and flow cytometric analysis were used to evaluate cell v</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2025-04-04T09:19:20.864Z</modification><creation>2025-04-04T09:19:20.864Z</creation></dates><accession>S-EPMC9887786</accession><cross_references><pubmed>36717845</pubmed><doi>10.1186/s12935-023-02853-6</doi></cross_references></HashMap>